News

New BIO Report Highlights Virginia’s Bioscience Industry Increases Jobs, NIH Awards and More

The Biotechnology Innovation Organization (BIO) released new data on the bioscience industry in the United States in their report, The Bioscience Economy: Propelling Life-Saving Treatments, Supporting State & Local Communities. This report outlines the bioscience industry’s economic footprint across the nation and in Virginia, as well as the significant role played by small- and mid-sized companies. The report further analyzes the industry’s response to the COVID-19 pandemic, and more broadly highlights the importance of the bio-ecosystem in times of pandemic, which requires rapid response and innovation.

The report recognizes Virginia at the national level for steady growth of NIH research funding and specialized employment in the bioscience, agricultural feedstock, and pharmaceutical subsectors. At the Commonwealth level, the bioscience industry outperformed the private sector with increases in wages and establishments. Virginia also experienced steady increases across the board in the bioscience industry as shown below.

● $86,212 average annual wage
● 24,346 employees
● 2,058 establishments
● $854M bioscience-related R&D expenditures
● $506.1M total NIH funding

”The bioscience industry plays a critical role in Virginia of creating jobs, quality wages, and innovative technologies. Virginia Bio is proud to serve as an advocate to our members whose businesses and technologies feed this bio-ecosystem. Members, who are in our own backyards, are working on life-saving technologies and reaching national recognition for their accolades. This bio-ecosystem must be protected to ensure vitality of this industry and to maintain its role as an economic driver in Virginia,” said John Newby, CEO of Virginia Biotechnology Association.

The state-by-state industry assessment is the ninth in a biennial series, developed in partnership by TEConomy and BIO, and studies the state of the U.S. bioscience industry and its associated innovation ecosystem at the national, state, and metropolitan area levels.

The analysis includes a fact sheet for Virginia, which can be found via the interactive map at www.bio.org/jobs.

Recent News

03/19/2026

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing

03/18/2026

Phlow Corp. Appoints Dawn Von Rohr as Chief Operating Officer to Advance Domestic Pharmaceutical Manufacturing

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dawn Von Rohr has been appointed Chief Operating Officer (COO). Von Rohr will oversee Phlow’s operations, manufacturing execution, and strategic growth initiatives as the company continues expanding its advanced pharmaceutical development and manufacturing infrastructure in the United States to

03/17/2026

W&M Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like